SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the “Selling Stockholder”) have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
